Comparison of analgesic effects of different doses of esketamine in day surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062255

Enrollment

Unknown

Registered

2022-07-31

Start date

2022-07-31

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group 1:Esketamine

Control group:Sufentanil

Experimental group 2:Esketamine 0.5/kg

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 ~ 65 years; 2. Patients undergoing hernia repair or cholecystectomy; 3. ASA grade ? ~ ?; 4. Sign informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Known allergy to the active ingredients or excipients of Esketamine hydrochloride injection; 2. Patients with uncontrolled hypertension (arterial hypertension, resting systolic blood pressure over 180mmHg, or resting diastolic blood pressure over 100mmHg); 3. Patients with severe QT interval prolongation; 4. Patients with heart, liver, kidney dysfunction and mental disorders; 5. Body mass index > 30kg/m^2; 6. A history of drug or alcohol abuse; 7. Patients who used analgesics or opioids within 12 hours before surgery; 8. Pregnant or lactating patients; 9. Untreated or undertreated hyperthyroidism.

Design outcomes

Primary

Measure	Time frame
Pain score;	—

Countries

China

Contacts

Public ContactSun Defeng

sdf-yl@163.com+86 18098876191

Outcome results